查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552551

骨質疏鬆症治療藥物市場規模、佔有率和趨勢分析報告：按藥物類別、類型、分銷管道、地區和細分市場預測，2024-2030年

Osteoporosis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Branded, Generics), By Type (Bisphosphates, Parathyroid Hormone Therapy), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

骨質疏鬆症治療市場的成長與趨勢

Grand View Research, Inc.最新報告顯示，到2030年，全球骨質疏鬆症治療市場規模預計將達到188億美元，2024年至2030年複合年成長率為3.5%。

據估計，不健康生活方式的激增將導致骨質疏鬆症惡化和盛行率增加，從而推動預測期內骨質疏鬆症治療市場的發展。

此外，專利到期數量的增加增加了使用現有藥物藥物學名藥的臨床緊迫性，預計這將在預測期內推動非專利骨質疏鬆症治療市場的發展。上述因素的結合顯示未來幾年存在巨大的潛在成長機會。

此外，加強提高患者和醫生對骨質疏鬆症治療的意識層級也有望擴大預測期內骨質疏鬆症市場的成長潛力。例如，國家骨質疏鬆症基金會 (NOF) 是一家負責國家骨骼健康聯盟和骨折聯絡服務 (FLS) 護理協調計劃的醫療保健組織，該組織致力於提高意識層級並向醫療保健專業人員提供培訓。

骨質疏鬆症治療市場報告亮點

  • 到2023年，品牌藥將在產品領域佔據壓倒性佔有率。這一主導佔有率是由於雙磷酸鹽、活化因數配體抑制劑的廣泛使用，它們在治療骨質疏鬆症方面具有高效能。
  • 由於未來幾年專利持續到期以及新興市場對負擔得起的藥物的高度臨床緊迫性，預計學名藥將繼續保持良好的複合年成長率。
  • 2023年，由於現有公司廣泛參與品牌治療的商業化，北美在全球骨質疏鬆症治療市場中佔據最大佔有率。
  • 由於政府採取積極舉措宣傳骨質疏鬆症治療相關訊息，預計亞太地區將以指數複合年成長率成長。
  • 主要參與企業正在採取永續性策略，以加速骨質疏鬆症治療的採用，以獲得競爭優勢。例如，阿特維斯公司宣布收購 Warner Chilcott PLC 以擴大產品系列。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章全球骨質疏鬆症治療市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 全球骨質疏鬆症治療市場分析工具
    • 波特的分析
    • PESTEL分析

第4章全球骨質疏鬆症治療市場：藥物類別、估計與趨勢分析

  • 細分儀表板
  • 全球骨質疏鬆症治療市場：2023 年和 2030 年藥物類別變化分析
  • 品牌
  • 非專利的

第5章全球骨質疏鬆症治療市場：類型、估計與趨勢分析

  • 細分儀表板
  • 全球骨質疏鬆症治療市場：類型變異分析，2023 年和 2030 年
  • 雙磷酸鹽
  • 副甲狀腺素治療
  • 抑鈣素
  • 選擇性雌激素抑制劑調變器
  • 活化因數配體抑制劑
  • 其他

第6章全球骨質疏鬆治療市場：通路、估計與趨勢分析

  • 細分儀表板
  • 全球骨質疏鬆症治療市場：2023年及2030年通路波動分析
  • 醫院藥房
  • 零售藥房
  • 線上

第7章全球骨質疏鬆症治療市場：區域估計與趨勢分析

  • 2023年及2030年全球骨質疏鬆症治療市場佔有率（按地區），百萬美元
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Amgen Inc.
    • Eli Lilly and Company
    • Merck &Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • GlaxoSmithKline plc.
    • Radius Health, Inc.
    • UCB SA
    • Teva Pharmaceutical Industries Ltd.
    • Roche Holding AG
簡介目錄
Product Code: GVR-1-68038-762-9

Osteoporosis Drugs Market Growth & Trends:

The global osteoporosis drugs market size is expected to reach USD 18.80 billion by 2030 and is projected to grow at a CAGR of 3.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.

In addition, growing number of patent expiries is fueling the high clinical urgency to use generic versions of the established drugs, which is presumed to fuel generic osteoporosis drugs market during the forecast period. The aforementioned factors cumulatively are slated to present the with high potential growth opportunities over the coming years.

Furthermore, rising number of initiatives to increase the awareness levels pertaining to osteoporosis care amongst the patients as well as the physicians is expected to widen the osteoporosis market growth potential during the forecast period. For instance, National Osteoporosis Foundation (NOF), a healthcare organization responsible for National Bone Health Alliance and Fracture Liaison Service (FLS) care coordination programs that focuses on elevating awareness levels as well as provides training to healthcare professionals

Osteoporosis Drugs Market Report Highlights:

  • Branded drugs held the dominant share of the product segment in 2023. The dominant share can be attributed to extensive utilization of bisphosphates, rank ligand inhibitors for the treatment of osteoporosis, possessing high efficacy
  • Generics are expected to witness at a lucrative CAGR owing to consistent patent expiries over the coming years as well as high clinical urgency for inexpensive medication in the emerging economies
  • In 2023, North America accounted for the largest share in the global osteoporosis drugs market owing to the presence of established companies extensively involved in the commercialization of branded therapeutics
  • Asia Pacific is anticipated to grow at an exponential CAGR as a consequence of favorable government initiatives promoting information pertaining to osteoporosis care
  • The key participants are employing sustainability strategies promoting the adoption of osteoporosis therapeutics to gain competitive advantage. For instance, Actavis Inc. announced to acquire Warner Chilcott PLC in order to widen their product portfolio

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Osteoporosis Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Global Osteoporosis Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Global Osteoporosis Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Osteoporosis Drugs Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Branded
    • 4.3.1. Branded Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Generics
    • 4.4.1. Generics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Global Osteoporosis Drugs Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Osteoporosis Drugs Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Bisphosphonates
    • 5.3.1. Bisphosphonates Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Parathyroid Hormone Therapy
    • 5.4.1. Parathyroid Hormone Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Calcitonin
    • 5.5.1. Calcitonin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Selective Estrogen Inhibitors Modulator
    • 5.6.1. Selective Estrogen Inhibitors Modulator Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Rank Ligand Inhibitor
    • 5.7.1. Rank Ligand Inhibitor Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Global Osteoporosis Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Osteoporosis Drugs Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacy
    • 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online
    • 6.5.1. Online Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Global Osteoporosis Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Global Osteoporosis Drugs Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Amgen Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Eli Lilly and Company
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Merck & Co., Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Novartis AG
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Pfizer Inc.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. GlaxoSmithKline plc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Radius Health, Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. UCB S.A.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Teva Pharmaceutical Industries Ltd.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Roche Holding AG
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives